Teva Pharmaceutical Industries Ltd. ADR 1.14% $25.35B ...

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...

After hours: December 27 at 7:38:58 PM EST Loading Chart for GSK ...

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis. The two-stranded collaboration will ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a price target of £16.90. The company’s shares closed today at p1,321. ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today. The company’s shares opened today at p1,388.50. Pick the best stocks and maximize ...

One year after a potential $1.7 billion deal with Hansoh Pharma, GSK goes back to China to forge another alliance with DualityBio for another deal that could be worth up to $1 billion as it continues ...

The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...

(Alliance News) - GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secondary target. Read More ...

Shares in GSK lost 8% of their value today in the wake of the analyst comments, while Sanofi fell 3% and Haleon was down 6%, collectively wiping tens of billions of dollars off their valuations.

The biggest stories of the day delivered to your inbox.